Phase I Dose-Escalation Study of RiMO-401 With Radiation in Advanced Tumors
Latest Information Update: 13 Mar 2024
At a glance
- Drugs RiMO 401 Coordination Pharmaceuticals (Primary)
- Indications Head and neck cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Coordination Pharmaceuticals
- 05 Mar 2024 Status changed from not yet recruiting to recruiting.
- 05 Feb 2024 Planned initiation date changed from 1 Jan 2024 to 1 Feb 2024.
- 01 Jan 2024 New trial record